GSH ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3
299	嚢胞性線維症	3

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05266417 (ClinicalTrials.gov)	February 7, 2022	23/2/2022	Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)	Parkinson Disease	Drug: INS-GSH;Drug: Matched Placebos	Gateway Institute for Brain Research	NULL	Recruiting	30 Years	85 Years	All	56	Phase 2	United States
2	NCT01398748 (ClinicalTrials.gov)	July 2012	19/7/2011	Intranasal Glutathione in Parkinson's Disease	A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease	Parkinson's Disease (PD)	Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery	Bastyr University	National Center for Complementary and Integrative Health (NCCIH)	Completed	21 Years	100 Years	All	34	Phase 1	United States
3	NCT01177319 (ClinicalTrials.gov)	September 2003	5/8/2010	Glutathione (GSH) In The Treatment of Parkinson's Disease	Glutathione (GSH) In The Treatment of Parkinson's Disease	Parkinson's Disease	Drug: Glutathione	University of South Florida	Wellness Health & Pharmaceuticals, Inc.	Completed	18 Years	N/A	Both	20	Phase 2	United States

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01450267 (ClinicalTrials.gov)	June 2010	30/9/2011	Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis	Randomized, Single Blind, Controlled Trial of Inhaled Glutathione Versus Placebo in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Inhaled Reduced Glutathione;Drug: Physiological solution	Serafino A. Marsico	Federico II University	Recruiting	6 Years	45 Years	Both	150	Phase 3	Italy
2	EUCTR2008-005080-33-IT (EUCTR)	05/02/2009	19/01/2009	RANDOMIZED, SINGLE BLIND, CONTROLLED TRIAL OF INHALED GLUTATHIONE VERSUS PLACEBO IN PATIENTS WITH CYSTIC FIBROSIS. - INHALED GSH VS PLACEBO IN CYSTIC FIBROSIS	RANDOMIZED, SINGLE BLIND, CONTROLLED TRIAL OF INHALED GLUTATHIONE VERSUS PLACEBO IN PATIENTS WITH CYSTIC FIBROSIS. - INHALED GSH VS PLACEBO IN CYSTIC FIBROSIS	Cystic fibrosis. MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung	Trade Name: TAD 600 INN or Proposed INN: Glutathione	AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
3	EUCTR2005-003870-88-DE (EUCTR)	20/10/2006	28/08/2006	Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4	Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4	Cystic fibrosis (CF) is the most common autosomal recessive lethal hereditary disorder in Caucasians. The majority of cystic fibrosis patients die as a result of progressive pulmonary disease. Airway inflammation, characterized by an excessive and persistent neutrophilic infiltration, is key for the pathogenesis of CF lung disease, and ultimately leads to lung destruction.	Product Name: GSH (Glutathione) Product Code: TAD 600 INN or Proposed INN: Glutathione Other descriptive name: reduced glutathione	Mukoviszidose Institut gGmbH i. G.	NULL	Not Recruiting			Female: yes Male: yes	160		Germany